Revolutionizing Non-Invasive Diagnostics with Plasmion’s SICRIT Breath Analysis.
Adagrasib Wins Accelerated Approval for KRAS-Mutant Colorectal Cancer
The FDA granted accelerated approval to adagrasib (Krazati) for KRAS G12C-mutated colorectal cancer (CRC), which accounts for 3-5% of CRCs. The approval stipulates use of